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ABSTRACT
Objective To determine the feasibility and optimal design 
of a randomised controlled trial (RCT) of Seizure First Aid 
Training For Epilepsy (SAFE).
Design Pilot RCT with embedded microcosting.
Setting Three English hospital emergency departments 
(EDs).
Participants Patients aged ≥16 with established epilepsy 
reporting ≥2 ED visits in the prior 12 months and their 
signiicant others (SOs).
Interventions Patients (and their SOs) were randomly 
allocated (1:1) to SAFE plus treatment- as- usual (TAU) or TAU 
alone. SAFE is a 4- hour group course.
Main outcome measures Two criteria evaluated a deinitive 
RCT’s feasibility: (1) ≥20% of eligible patients needed to be 
consented into the pilot trial; (2) routine data on use of ED 
over the 12 months postrandomisation needed securing 
for ≥75%. Other measures included eligibility, ease of 
obtaining routine data, availability of self- report ED data and 
comparability, SAFE’s effect and intervention cost.
Results Of ED attendees with a suspected seizure, 424 
(10.6%) patients were eligible; 53 (12.5%) patients and 38 SOs 
consented. Fifty- one patients (and 37 SOs) were randomised. 
Routine data on ED use at 12 months were secured for 94.1% 
patients. Self- report ED data were available for 66.7% patients. 
Patients reported more visits compared with routine data. 
Most (76.9%) patients randomised to SAFE received it and no 
related serious adverse events occurred. ED use at 12 months 
was lower in the SAFE+TAU arm compared with TAU alone, 
but not signiicantly (rate ratio=0.62, 95% CI 0.33 to 1.17). A 
deinitive trial would need ~674 patient participants and ~39 
recruitment sites. Obtaining routine data was challenging, 
taking ~8.5 months.
Conclusions In satisfying only one predetermined ‘stop/
go’ criterion, a deinitive RCT is not feasible. The low consent 
rate in the pilot trial raises concerns about a deinitive trial’s 
inding’s external validity and means it would be expensive 
to conduct. Research is required into how to optimise 
recruitment from the target population.
Trial registration number ISRCTN13871327
BACkgROunD
International evidence shows a significant 
minority of people with epilepsy (PWE) 
frequently use hospital emergency depart-
ments (EDs).1–4In the United Kingdom, 
around 20% of PWE visit each year, of which 
half are admitted.5–7 While the exact distri-
bution of use among attendees is unclear,8–10 
~60% may make several visits each year.11
Emergency hospital use by PWE has 
been identified as an area for potential cost 
savings,12as while expensive—approximately 
~£70–90 million in England each year8 13 14—it 
Strengths and limitations of this study
 Ź Randomisation was done remotely by computer and 
stratiication factors and allocations concealed from 
those collecting baseline and follow- up data and 
analysing it.
 Ź Participants were recruited from site’s serving ar-
eas, where social deprivation was high and epilepsy 
control poor and so similar to those where a dein-
itive randomised controlled trial (RCT) would likely 
need to focus recruitment.
 Ź We completed one of the few microcostings of a 
self- management intervention for epilepsy.
 Ź Despite recruited patient participants stating sufi-
cient emergency department use when screened, 
routine data subsequently suggested ~40% did not 
meet the inclusion criteria.
 Ź We estimated the effect of Seizure First Aid Training 
For Epilepsy only on the proposed primary outcome 
measure for a deinitive RCT.
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is often of little clinical benefit since most attendees have 
known, rather than new epilepsy and experienced uncom-
plicated seizures.9 15 16 Guidance states such seizures 
could be managed by PWE and their significant others 
(SOs).17 18 Indeed, iatrogenic harms may arise in seeking 
emergency care for them.
PWE visiting EDs have a characteristic profile. They 
report more seizures, anxiety, poorer quality of life and are 
more likely to live in socially deprived areas compared to 
the wider epilepsy population.11 19–22 They therefore share 
some of the characteristics of those at increased risk of 
epilepsy- associated death.23 24 In the UK, PWE visiting EDs 
can also be challenging to identify for research since most 
(~62%) are not being followed up by an epilepsy specialist,1 
primary care providers are also not always notified of ED 
visits by their patients9 and because EDs do not always code 
the reason for an attendance in sufficient detail.25
While the focus on PWE attending EDs is welcomed, it 
needs to be translated into care improvements. Although 
a range of promising interventions have been suggested,26 
assessment of their utility is lacking.27
One intervention proposed is seizure first aid training. 
It has potential as PWE frequently visiting EDs and their 
SOs (to whom care decisions can be delegated28 29) 
express particularly low knowledge and confidence in this 
domain, are fearful of seizures and there are indications 
this leads them to seek emergency medical attention for 
seizures, rather than self- managing them.30
As no such intervention existed, we developed one—
called Seizure First Aid Training For Epilepsy (SAFE). 
SAFE is a manualised group- based self- management 
course (table 1). It’s rationale and development has been 
reported.31 In brief, it was codesigned with health profes-
sionals, patients and carers. It was developed for delivery 
to groups of up to 10 patient–carer dyads by a single facil-
itator with knowledge of epilepsy and lasts for ~4 hours. 
It contains six modules centred around basic epilepsy 
and first aid knowledge, the recovery position, informing 
others about epilepsy and how to help if seizures occur, 
medical identification, seizure triggers and home safety. 
Materials include presentation slides and professionally 
produced videos. Its behaviour change potential has 
been optimised by course recipients completing a self- 
affirmation exercise at the start.
SAFE’s efficacy now needs testing. A randomised 
controlled trial (RCT) would be an appropriate method-
ology for this. ED use over the 12 months following rando-
misation could be the primary outcome. It is unknown 
whether such a trial is feasible and what its optimal design 
should be.
Specifically, will patients and their SOs take part, attend 
SAFE and be willing and able to be followed up? It is also 
not possible to calculate the required sample size because 
the distribution of ED use is unclear. These uncertainties 
exist because SAFE is newly developed and no RCT has 
attempted to recruit the target population.
It is also unclear how to measure ED visits. Funders are 
encouraging trialists to use routinely recorded data to 
assess outcomes. In England, routine data on a person’s 
ED use are recorded within the Hospital Episode Statis-
tics system. This data’s cost, how long it takes to obtain 
and its comparability to self- report are unknown.
In such circumstances, guidelines highlight the impor-
tance of pilots.32 Their primary focus is not effect, but 
judging feasibility and providing information to optimise 
a definitive RCT’s design.33 We thus completed a pilot 
RCT comparing SAFE plus treatment- as- usual (TAU) 
or TAU alone. It had the following objectives, which 
will be relevant to those interested in SAFE and those 
researching this population: (1) estimate likely eligi-
bility, consent and retention rates in a definitive RCT; (2) 
estimate annual rate of ED visits in TAU group and the 
likely dispersion parameter; (3) determine feasibility of 
measuring ED use by routine data; (4) estimate comple-
tion rates of study assessment tools; (5) estimate rates of 
researcher unblinding; (6) provide summary statistics to 
estimate effect of SAFE on ED use and its precision; (7) 
capture patient’s and SO’s views on trial participation; 
and (8) estimate the intervention’s cost.
MeThODS
The trial’s protocol has been published.30 Here we 
provide a brief overview.
Design
Parallel arm, multi- centre, external pilot RCT. Assessments 
with participants on the definitive trial’s proposed primary 
and secondary outcome measures were performed at 
baseline prior to randomisation (T0) and 12 months later 
(T3, table 2). Interim assessments occurred at 3 (T1) and 
6 months (T2).
SAFE was offered to the TAU alone group after T3 
assessments were completed.
Trial setting
Three hospitals in north- west England—which serve 
populations featuring high- social deprivation34 35 and 
emergency admissions for epilepsy21—were recruitment 
sites (see Acknowledgements section). From May to 
December 2016 patients were invited who had attended 
any of these hospital’s ED over the prior 12 (and with 
governance approval, later extended to 18) months for 
epilepsy (see Patient recruitment section).
ethical considerations and approvals
The National Research Ethics Service Committee (15/
NW/0225) and Health Research Authority (166241) 
approved the study. An independent Trial Steering 
Committee monitored the trial.
Patient recruitment
ED clinicians searched their hospitals’ attendance record 
systems for potential participants (online supplementary 
file 1), screened their triage cards and posted invitations 
to eligible patients. Recipients had 3 weeks to return an 
opt- out response if not interested in participating. Those 
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Table 1 SAFE course and its content
Overview
SAFE was developed to be delivered to groups of ~10 patient–SO dyads by a single facilitator with epilepsy knowledge who 
follows a treatment manual. Materials include standardised presentation slides, videos and interactive tasks. Patients are 
given information packs that include copies of the slides, wallet- sized irst aid instruction cards, paper epilepsy ID cards and 
instructions for setting up IDs on smartphone, and access to a website with the intervention’s content on.
  SAFE’s behaviour change potential is supported by reference to Self- Afirmation Theory.
SAFE’s order of presentation and content is as follows:
Order Topics Learning activity Minutes allotted
1 Welcome Slide 5
2 Goals of this course Slide 2
3 What would you like from today? Interactive 20
4 True or false? Interactive 12
5 Taking on information (Kindness Questionnaire) Interactive 10
6 Epilepsy, seizures and how the brain works Video 10
7 First aid for convulsive seizures Interactive 10
8 What can you do to help someone during a seizure? Slide 5
9 What not to do during a seizure Slide 5
10 What to do after the seizure has stopped Slide 5
11 Questions or comments? Interactive 10
12 Postseizure states Slide 15
13 Injuries Slide 2
14 When to call an ambulance? Slide 10
15 Questions or comments? Slide 10
16 Refreshment break Networking 10
17 Recovery position Slide 2
18 Recovery position Video 2
19 Let’s practice the recovery position Interactive 15
20 Questions or comments? Interactive 5
21 Who needs to know how to help? Interactive 5
22 What they need to know and why? Slide 5
23 How to get this information to them. Family, friends and work 
colleagues:
Slide 5
24 How to get this information to them. Members of the public 
and health workers:
Slide 5
25 Questions or comments? Interactive 5
26 Refreshment break Networking 5
27 Personal stories—introduction Slide 2
28 Ben’s story (case vignette) Slide 6
29 How to change what happened to Ben? (Carrying medical 
ID; triggers)
Interactive 5
30 Triggers Slide 5
31 Knowing your triggers Slide 4
32 Some ways of dealing with triggers Slide 4
33 Sandra’s story (case vignette) Slide 6
34 How to change what happened to Sandra (Warning signs; 
home safety)
Interactive 2
35 Main points to remember, If you have epilepsy: Slide 3
Continued
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Overview
36 Main points to remember; If you know someone with 
epilepsy:
Slide 2
37 Sources of further information Slide 2
38 What’s on the back table and accessing the study website* Slide 2
39 Questions or comments? Slide 2
40 Evaluation   –
41 Certiicates of attendance   –
Time in minutes: 240.
*http://www.seizureirstaid.org.uk/Intervention/.
SAFE, Seizure First Aid Training For Epilepsy; SO, signiicant other.
Table 1 Continued
not opting- out were telephoned by a researcher to verify 
eligibility and willingness to participate. Patients taking 
part (and their SO if they chose to take part with one) 
provided informed consent at an enrolment appoint-
ment with a researcher (DS). For patients, this included 
consent to access their routine data.
eligibility criteria
Table 3 details the criteria. In brief, patients were eligible 
if they were aged ≥16, diagnosed with epilepsy, prescribed 
antiepileptic drugs, could give informed consent and, 
when telephoned, self- reported ≥2 ED visits for epilepsy 
in the prior 12 months.
Randomizsation and blinding
Patients (and their SOs) were randomised (1:1) by an 
online system managed by the Liverpool Clinical Trials 
Centre. It used a minimisation programme with a built- in 
random element and two stratification factors (recruit-
ment site and whether the patient reported epilepsy 
stigma at baseline).
Usual care provider(s) and DS, who was responsible 
for recruitment and follow- up, were blinded to alloca-
tions and stratification factors. Participants could not be 
blinded and so were asked (and reminded at follow- ups) 
not to reveal their allocation to DS.
Staff (GM) organising attendance at SAFE were not 
involved in data collection and not blinded. The trial stat-
istician (SN) and senior statistician (CTS) were blinded 
until the database was ‘locked’.
Measures to assess patient and SO participants’ outcomes
Table 2 details these measures.
Intervention
An epilepsy nurse specialist (JB) delivered SAFE within a 
local hospital’s educational centre. A fidelity assessment 
found they delivered SAFE with excellent protocol adher-
ence and competence.36
Outcomes
To achieve the study objectives, rates of eligibility, 
consent and retention were calculated. Retention being 
the percentage of patients for which 12- month primary 
outcome data were secured. Two a priori progression 
criteria helped judge feasibility: (1) ≥20% of eligible 
patients were recruited; (2) 12- month primary outcome 
data were secured for ≥75% of patients.
By assessing participants on the proposed outcome 
measures, we obtained estimates of the distribution of 
ED use, measure completeness and SAFE’s effect. To eval-
uate blinding, DS completed a ‘Treatment Guess’ form 
after each participant’s T3 assessment or withdrawal. It 
required her to state which treatment arm she believed 
the participant had been randomised to. The propor-
tion of participants willing to participate in such a trial 
again was ascertained and experience of adverse events 
calculated. Time taken to obtain routine data and the fee 
payable were recorded. To see if self- reported ED visits 
provided a reliable estimate compared with routine data, 
the agreement between the two data sources on how 
many ED visits a patient had made was explored.
Statistical analyses
As this was a pilot RCT, a power calculation was inappro-
priate. Instead, the sample size was chosen to provide 
adequate precision to estimate the parameters required.37
Based on existing data,1 14 16 38 39 it was anticipated that 
12 months of attendances from each ED would allow iden-
tification of ~400 eligible patients. With a 20% consent 
rate, 80 patient participant accruals could be expected. 
With 80 patient participants we could estimate a potential 
drop- out rate of 25% to within a 95% CI of ±10% and a 
consent rate of 20% to within a 95% CI of ±4%. Assuming 
ED data at T3 was not available for 25% of patients, data 
from 60 patients would still allow robust estimation of 
the ED rate and dispersion parameter. Sample sizes of 
24 to 50 have been recommended as ‘adequate’ for pilot 
studies.37 40
Analyses were documented a priori in an analysis plan 
and performed using SAS (V.9.4). Baseline characteris-
tics for patient and SO participants are described using 
descriptive statistics and patient participants compared, 
on a subset, to eligible patients declining participation. 
Parameters are reported with 95% CIs.
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Table 2 Proposed primary and secondary outcome measures for a deinitive trial used within pilot trial by assessment and 
participant type*
Outcome Domain Participants Measure and derivation of outcome Baseline (T0)
3 Months 
(T1)
6 Months 
(T2)
12 Months 
(T3)
Primary ED visits PWE Routine data, Hospital Episode Statistics 
Accident and Emergency system.
✓ – – ✓
NHS numbers of patient participants securely 
transferred to NHS Digital who hold the Hospital 
Episode Statistics system. NHS Digital then 
provided the number of ED visits these patients 
were recorded as having made in the 12 months 
prior to and in the 12 months following their 
randomisation.†
Secondary ED visits PWE Self- report, ‘How many times have you used 
Casualty/A&E over the past 12 months for 
epilepsy?’
✓ – ✓ ✓
(For T2 the time frame was 6 months).
Provided with seizure diary at T0 to assist.
Seizure 
control
PWE Baseline: Thapar et al’s64 Seizure Frequency 
Scale for the prior 12 months.
✓ – ✓ ✓
T2 and T3: asked for number of epileptic seizures 
(of any type) since last assessment and dates of 
the irst and most recent. Provided with seizure 
diary at T0 to assist.
Quality of life PWE Quality of Life in Epilepsy Scale-31- P (31 items)65 ✓ – ✓ ✓
Distress PWE; SOs Hospital Anxiety and Depression Scale(14 
items)66‡
✓ – – ✓
Felt stigma PWE; SOs Stigma of Epilepsy Scale(9 items).67§ ✓ – – ✓
Burden SOs Zarit Caregiver Burden Inventory (22 items).49¶ ✓ – ✓ ✓
Adverse 
events
PWE Monitored by PWE completing a checklist** – ✓ ✓ ✓
Fear of 
seizures
PWE, SOs Epilepsy Knowledge and Management 
Questionnaire—Fears subscale (5 items).68
✓ – – ✓
Knowledge 
of what to do 
when faced 
with a seizure
PWE, SOs Thinking About Epilepsy Questionnaire (13 
items)69
✓ – – ✓
Conidence 
managing 
seizures/ 
epilepsy
PWE, SOs PWE: Epilepsy Mastery Scale (6 items).70 ✓ – ✓ ✓
SOs: Parents Response to Child Illness Scale- 
Condition Management subscale (6 items).71
Health 
economics
PWE Client Service Receipt Inventory72 and EQ- 5D(13 
items)73
✓ – – ✓
– Feedback 
on trial 
participation
PWE, SOs Adapted from Magpie Trial(3 items)74 – – – ✓
(1) ‘If time suddenly went backward, and you 
had to do it all over again, would you agree to 
participate in the Seizure First Aid Training trial?’
(2) ‘Please tell us if there was anything about 
the Seizure First Aid Training Trial that you think 
could have been done better’.
(3) ‘Please tell us if there was anything about the 
Seizure First Aid Training Trial, or your experience 
of joining the trial, that you think was particularly 
good’.
*Unless a patient formally withdrew consent to participate in the trial, routine data on their ED use were requested and up to three attempts were made to contact 
patients or SO participant each time one of their follow- up assessments was due.
†To minimise cost, a single application for routine data was submitted, rather than one relating to the baseline period and one for follow- up.
‡Total anxiety and total depression scores were categorised according to the following: 0–7, ‘Normal range’; 8–10, ‘Suggestive of anxiety/depression’; 11–21, 
‘Probable anxiety/depression.’.
§Total stigma scores were categorised as follows: 0, ‘No stigma’; 1– 6, ‘Mildly to moderately stigmatised’; 7–9, ‘Highly stigmatised.
¶Total Zarit Burden scores were categorised as follows: 0–20, ‘Little or no burden’; 21–40, ‘Mild to moderate burden’; 41–60, ‘Moderate to severe burden’; 61–88, 
‘Severe burden.’.
**Deinitions of serious adverse event and how relatedness was assessed is presented in online supplementary ile 9.
A&E, Accident & Emergency ; ED, emergency department; EQ- 5D, EuroQol-5 Dimensions; NHS, National Health Service; PWE, Person with epilepsy; SOs, 
signiicant others.
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Table 3 Participant inclusion and exclusion criteria
Participants Inclusion criteria Exclusion criteria
Patients Established diagnosis of epilepsy (≥1 year) Actual or suspected psychogenic non- epileptic seizures alone or in 
combination with epilepsy.
All epilepsy syndromes and all types of 
focal and generalised seizures
Acute symptomatic seizures related to acute neurological illness or 
substance misuse.
Currently being prescribed antiepileptic 
medication
Severe current psychiatric disorders (eg, acute psychosis) or life- 
threatening medical illness.
Age ≥16 years (no upper age limit) Enrolled in other epilepsy related non- pharmacological treatment 
studies.
Visited an ED for epilepsy on ≥2 occasions 
within the previous 12 months (as reported 
by patient)
Lives within 25 miles of any of the ED 
recruitment sites
Able to provide informed consent, 
participate in intervention and 
independently complete questionnaires in 
English
Signiicant 
others
A SO to the patient (eg, family member, 
friend) who the patient identiies as 
providing informal support
Severe current psychiatric disorders or life threatening medical 
illness.
Age ≥16 years (no upper age limit) Enrolled in other epilepsy related non- pharmacological treatment 
studies.
Lives in the north- west area of England
Patient participants were permitted to take part without a signiicant other . Signiicant others could not, however, take part 
without a patient partner having at least consented to take part into the study.
ED, emergency department; SO, signiicant other.
SAFE’s effect on ED use, with and without adjustment 
for number of ED visits prior to randomisation, was esti-
mated using negative binomial regression (NBR) on a 
modified intention- to- treat basis (as defined by Del Re 
et al.41). Participants were included with their number 
of ED visits recorded with no data imputation. NBR was 
the prespecified statistical approach as over- dispersion 
(ie, large variance) was anticipated in the number of ED 
visits reported. Between- group differences are presented 
as rate ratios and, as per recommendations for hypothesis 
testing within pilot trials,42 tested according to 5, 10% and 
20% levels of significance.
The proportion of correct treatment guesses was deter-
mined and Cohen’s Kappa computed. Bland- Altman 
plots compared ED visits as measured by routine data and 
self- report.43
As no consensus exists about what constitutes a clini-
cally important reduction in ED visits,44 average annual 
rate of ED visits in the SAFE+TAU and TAU alone groups 
postrandomisation (measured according to routine data) 
and the likely dispersion parameter from the adjusted 
NBR model were used to estimate the sample size of a 
definitive trial using Keene et al’s45 formula. According to 
the formula, the number of patient participants required 
per group in a definitive trial to detect the size of the 
effect shown in the pilot study is:
 
O 
{;−β;−α
MPH	µµ

}
×
{
µµ
µµ  ,
}
 
where Z
1−α/2
 and Z
1−β are critical values of the normal 
distribution for specific values of alpha (α) and power 
(β). µ
1
 and µ
2
 are the estimated ED rates from the two 
treatment groups and k the negative binomial shape 
parameter from the associated gamma distribution which 
explicitly represents variability between subjects. For 
the calculations, alpha was set at 5%, but the dispersion 
parameter and power required was varied to explore 
differences in sample size required.
Microcosting
Microcosting adopted the perspective of an academic 
non- profit making institution and was conducted in 
three steps46: (1) resource identification; (2) resource 
use measurement, applying the time and motion 
method47; and (3) valuation using price year 2017/2018 
for local and national data. Data were analysed using 
Microsoft Excel 2010 to calculate the fixed and variable 
costs of delivering SAFE. Fixed costs included, equip-
ment, website, freepost licence, venue hire, facilitator 
staff cost and facilitation resources; and assumed 11 
groups/year and equipment life of 1 year. Variable costs 
were support staff and office costs, staff and participant 
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Figure 1 CONSORT diagram of low through the pilot trial. 
CONSORT, Consolidated Standards of Reporting Trials; SOs, 
signiicant others.
travel expenses and consumables. Total cost per group 
was calculated as fixed costs plus variable costs, for each 
group and each arm (SAFE+TAU; TAU). Mean cost per 
group was calculated as the sum of total costs/number 
of groups. Mean cost per delegate (or patient only) was 
calculated as sum of total cost per group in each arm/
sum of delegates (or patients only) in each arm. Results 
are presented as cost per training session, mean cost per 
delegate and mean cost per patient. The 95% central 
range (CR) for costs and differences were generated 
using Monte Carlo Simulation of 10 000 replications.
Patient and public involvement statement
This research came about as improving education 
for patients and families on epilepsy is a top research 
priority.48 To ensure SAFE was developed and tested in 
a way that met service users' needs the ‘Epilepsy Society’ 
and patient and SO representatives from the ‘Brain 
and Spine Foundation’ helped develop recruitment 
materials; the pilot was overseen by a Trial Steering 
Committee including two service user representatives; 
SAFE was designed by an Intervention Panel including 
two service user representatives and its content 
informed by feedback from 23 service users31; finally, 
pilot trial participants reported on the burden of partic-
ipation with a view to optimising the design of a poten-
tial definitive RCT.
ReSulTS
Participant recruitment, allocation and treatment
Of the 4016 individuals identified, 1220 (30.4%, 95% CI 
29.0% to 31.8%) had visited for established epilepsy. Of 
these, 424 (34.8%, 95% CI 32.1% to 37.4%) were eligible; 
eligibility rate 10.6% (95% CI 9.6% to 11.5%, figure 1, 
online supplementary file 2).
Of the 424 patients invited, 53 consented; consent rate 
was 12.5% (95% CI 9.3% to 15.6%). Telephone contact 
could only be made with 203 (47.8%, 95% CI 43.1% to 
52.6%) patients. The consent rate among those who 
could be contacted was 26.1% (95% CI 20.0% to 32.2%). 
The main reasons for 150 patients declining participation 
were ‘lack of interest’ (42.7%, 95% CI 34.8% to 50.6%) 
and being ‘too busy’ (22.6%, 95% CI 16.0% to 29.4%).
Of the 53 consenting patients, 51 were randomised (with 
37 SOs, figure 1 gives reasons for non- randomisation). Of 
the 51, 26 (and 18 SOs) were allocated to SAFE+TAU and 
25 (and 19 SOs) to TAU alone. Most (20, 76.9%) patients 
and SOs (13, 72.2%) randomised to SAFE+TAU attended 
a course.
Participant demographics and epilepsy characteristics
The patient participants mean age was 39.9 years (SD 15.7, 
range 16–71); 29 (56.9%) were female and most (74.4%) 
lived in areas high in deprivation (49% in the 10% most 
socially deprived areas in England, table 4).
Recruited patients were comparable in age and depri-
vation to those declining participation. Females were 
over- represented (table 4).
Recruited patients had an epilepsy diagnosis for a 
median of 17.3 years. Most (62.8%) patients reported ≥10 
seizures in the previous year and having seen a neurol-
ogist (74.5%, table 4). Participants’ mean Quality of 
Life-31- P score was low at 48.3 (SD 17.3; range 17.1 to 
79.5). Twenty- six (50.9%) patients had ‘probable’ clinical 
anxiety. Most (n=42, 82.3%) patients reported feeling 
stigmatised by epilepsy; 15 (29.4%) highly. The treat-
ment groups were broadly similar in demographics and 
epilepsy characteristics.
SO participants were typically a partner/spouse 
(43.2%) and most (89.2%) had daily patient contact 
(online supplementary file 3). With a mean Zarit Care-
giver burden score of 18.9 (SD=12.51), SOs typically 
reported ‘little or no burden’49 but anxiety was high50; 15 
(40.5%) SOs had ‘probable’ clinical anxiety.
Participant retention
Proposed primary outcome measure
Of the randomised patients, 3 (5.8%) formally withdrew 
over follow- up, removing access to their routine data. 
Primary outcome data on ED use at 12 months (and for 
the 12 months prior to randomisation) were available 
for the remaining 48 patients, giving a retention rate of 
94.1%.
Proposed secondary outcome measures
Thirty- seven (72.5%) randomised patients and 21 
(56.8%) SOs attended their 12 months questionnaire 
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Table 4 Characteristics of eligible patients who did and did not agree to participate
Variable
Agreed to participate
Did not agree to 
participate
SAFE+TAU TAU Combined
(n=26) (n=25) (n=51) (n=379)*
Sex: n (%)
  Male 10 (38.5%) 12 (48.0%) 22 (43.1%) 192 (50.7%)
  Female 16 (61.5%) 13 (52.0%) 29 (56.9%) 187 (49.3%)
Age at presentation to ED (years)
  Mean 39.2 40.7 39.9 40.6
  SD 13.96 17.52 15.66 16.83
  Median (min, max) 37.1 (18.9 to 69.9) 41.4 (16.5 to 71.3) 38.8 (16.4 to 71.3) 37.5 (16.2 to 84.4)
IMD†
  IMD decile: 1 n (%) 11 (42.3%) 14 (56.0%) 25 (49.0%) 188 (49.6%)
  IMD rank Median (min, max) 574.0 (44 to 3202) 1231.5 (48 to 2166) 673.0 (44 to 3202) 924.5 (28 to 3107)
  IMD decile: 2–3 n (%) 7 (26.9%) 6 (24.0) 13 (25.4%) 82 (21.6%)
  IMD rank Median (min, max) 6785 (4649 to 8281) 6665 (3989 to 7816) 6785 (3989 to 8281) 5309 (3291 to 9835)
  IMD decile: 4–6 n (%) 2 (7.7%) 4 (16.0%) 6 (11.8%) 59 (15.6%)
  IMD rank Median (min, max) 128 366 (9881 to 15791) 119 244 (11 480 to 
16004)
119 244 (9881 to 16004) 144 599 (10 277 to 19 659)
  IMD decile: 7–10 n (%) 5 (19.2%) 1 (4.0%) 6 (11.8%) 50 (13.2%)
  IMD rank Median (min, max) 276 422 (24 971 to 31 
002)
327 244 (32 724 to 32 
724)
288 766 (24 971 to 32 
724)
226 733 (19 826 to 32 396)
  Missing 1 (3.8%) 0 (0.0%) 1 (2.0%) 0 (0.0%)
Ethnicity: n (%)
  White 25 (96.2%) 23 (92.0%) 48 (94.1%) –
  Asian/Asian British 0 (0.0%) 0 (0.0%) 0 (0.0%) –
  Black/African/Caribbean/Black British 1 (3.8%) 1 (4.0%) 2 (3.9%) –
  Mixed/multiple ethnic groups 0 (0.0%) 0 (0.0%) 0 (0.0%) –
  Other ethnic group 0 (0.0%) 1 (4.0%) 1 (2.0%) –
Other signiicant medical history: n (%)
  No, none 13 (50.0%) 10 (40.0%) 23 (45.1%) –
  Yes, another medical condition/s 10 (38.5%) 13 (52.0%) 23 (45.1%) –
  Yes, a psychiatric condition 1 (3.8%) 0 (0.0%) 1 (2.0%) –
  Yes, both medical and psychiatric 
conditions
2 (7.7%) 2 (8.0%) 4 (7.8%) –
Education: n (%)
  O' levels/GCSEs/level 1 or 2 NVQ 13 (50.0%) 14 (56.0%) 27 (53.0%) –
  A' levels/level 3 NVQ 5 (19.2%) 3 (12.0%) 8 (15.7%) –
  University degree/graduate certiicate or 
diploma
5 (19.2%) 5 (20.0%) 10 (19.6%) –
  Postgraduate university degree (eg, 
PGCE, MSc, MA, PhD)
2 (7.7%) 0 (0.0%) 2 (3.9%) –
  Missing 1 (3.9%) 3 (12.0%) 4 (7.8%) –
Time since epilepsy diagnosis (years)
  Mean 19.9 22.6 21.2 –
  SD 14.85 18.38 16.57 –
  Median (mix, max) 16.8 (1.8 to 53.9) 19.3 (1.7 to 64.9) 17.3 (1.7 to 64.9) –
Time since last epileptic seizure (days)
  Mean 53.6 40.1 47 –
  SD 101.1 61.21 83.34 –
  Median (min, max) 14.0 (1 to 340) 10.5 (0 to 235) 14.0 (0 to 340) –
Continued
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Variable
Agreed to participate
Did not agree to 
participate
SAFE+TAU TAU Combined
(n=26) (n=25) (n=51) (n=379)*
  Missing 3 (11.5%) 3 (12.0%) 6 (11.8%) –
Number of epileptic seizures in the last 
12 months
  0–3 4 (15.3%) 3 (12.0%) 7 (13.8%) –
  6- April 1 (3.8%) 5 (20.0%) 6 (11.7%) –
  9- July 3 (11.5%) 3 (12.0%) 6 (11.7%) –
  10 or more 18 (69.2%) 14 (56.0%) 32 (62.8%) –
*Includes seven patients who could not be contacted due to an incorrect postal address and two patients who were not sent an invite letter in error. min=minimum, 
max=maximum.
†The IMD ranks every small area in England from 1 (most deprived area) to 32 844 (least deprived area). IMD rank and decile missing for one recruited participant as 
they resided in Wales.
GCSE, General Certiicate of Secondary Education; IMD, Index of Multiple Deprivation; NVQ, National Vocational Qualiication; SAFE, Seizure First Aid Training For 
Epilepsy; TAU, treatment- as- usual.
Table 4 Continued
Table 5 Number of ED visits patient participants made according to routine data
Number of ED visits
SAFE+TAU
(n=26)
TAU
(n=25)
Total
(n=51)
In the 12 months to baseline
  Mean 2.1 3 2.5
  SD 2.22 2.76 2.51
  Median (min, max) 1 (0 to 10) 2 (1 to 12) 2 (0 to 12)
  Missing 1 (3.8%) 2 (8.0%) 3 (5.9%)
In the 12 months following randomisation
  Mean 1.8 3.4 2.6
  SD 3.14 4.78 4.05
  Median (min, max) 1 (0 to 12) 2 (0 to 20) 1 (0 to 20)
  Missing 1 (3.8%) 2 (8.0%) 3 (5.9%)
Change from baseline over 12 months following randomisation
  Mean −0.3 0.4 0.1
  SD 1.99 3.81 2.99
  Median (min, max) 0 (-4 to 5) 0 (–5 to 16) 0 (–5 to 16)
  Missing 1 (3.8%) 2 (8.0%) 3 (5.9%)
ED, emergency department; SAFE, Seizure First Aid Training For Epilepsy; TAU, treatment- as- usual.
appointment (T3). The extent to which measures were 
completed at these and the interim appointments varied 
(online supplementary file 4). Self- report data on ED use 
at T3 was obtained from only 34 patients, giving a reten-
tion rate on this measure of 66.7% patients.
eD use
Baseline, prior to randomisation
Routine data for the 48 patients for whom consent was 
maintained showed they made 122 ED visits in the 12 
months before randomisation (online supplementary file 
5). The mean was 2.5 and median 2 (range 0 to 12). ED 
use was slightly higher for TAU participants (table 5).
Despite only consenting patients who when telephoned 
reported ≥2 ED visits in the prior 12 months, routine data 
indicated 4 (8.3%) had not made any visits during the 
prior 12 months. A further 19 (39.6%) made only one.
At 12 months, effect of SAFE
Compared with the 12 months prior to randomisation, 
mean ED use over follow- up reduced for the SAFE+TAU 
group from 2.1 visits to 1.8 (difference −0.3). For the 
TAU group, it increased from 3 visits to 3.4 (difference 
0.4, table 5). Unadjusted NBR estimated the visit rate 
was 46% lower in the SAFE+TAU group compared with 
the TAU group (rate ratio=0.54; Vuong’s test z=−0.17, 
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Table 6 Between- group intervention differences in number of ED visits
Model and parameter Parameter
CI
P value95% 90% 80%
12 Months following randomisation according to routine data*
  Negative binomial: SAFE+TAU (rate 
ratio)
0.54 0.24 to 1.18 0.28 to 1.04 0.32 to 0.90 0.12
  Negative binomial: dispersion 
parameter
1.53 0.67 to 2.39 0.80 to 2.25 0.96 to 2.09 NA
  Vuong’s test† −0.17 NA NA NA 0.87
12 Months following randomisation according to routine data with adjustment for baseline ED visits
  Negative binomial: SAFE+TAU (rate 
ratio)
0.62 0.33 to 1.17 0.36 to 1.06 0.41 to 0.94   0.14
  Negative binomial: Baseline ED visits 
(rate ratio)
1.33 1.18 to 1.52 1.20 to 1.49 1.23 to 1.45 <0.001
  Negative binomial: Dispersion 
parameter
0.69 0.17 to 1.21 0.26 to 1.13 0.35 to 1.03 NA
  Vuong’s test† −0.13 NA NA NA 0.90
*Analysis based on 48 patient participants.
†Vuong’s test p value interpretation, a signiicantly negative parameter value favours the negative binomial model and signiicantly 
positive favours the zero- inlated negative binomial model. A non- signiicant value indicates no signiicant difference between the models 
therefore the simpler negative binomial model is preferred.75
.ED, emergency department; SAFE, Seizure First Aid Training For Epilepsy; TAU, treatment- as- usual.
Figure 2 (A) Bland- Altman plot of agreement between self- 
reported ED use and routine data on ED use in 12 months 
prior to randomisation. (B) Bland- Altman plot of agreement 
between self- reported ED visits and routine data on ED use 
over 12 months following randomisation. ED, emergency 
department; SAFE, Seizure First Aid Training For Epilepsy.
p=0.87). In the adjusted model, SAFE’s effect reduced 
(rate ratio=0.62). Between- group differences were not 
significant at the 5% or 10% alpha level in either the 
unadjusted or adjusted model. The effect was significant 
in both at the 20% level (table 6). The dispersion param-
eter under the adjusted NBR model was k=0.69 (CI 0.17 
to 1.21).
Obtaining routine data and its correspondence with self-
report
Routine data took 8.5 months to secure, arriving 
~9 months after T3 assessments finished. The direct cost 
was £6960. Online supplementary file 6 shows substantial 
work on behalf of the research team to obtain the data was 
required. In one instance, an appeal against a decision to 
reject the application—5 months in—was necessary.
Routine data did not match patient self- report in most 
cases. Forty- two patients had self- report and routine data 
on ED use at baseline. Only 3 (7.1%) reported the same 
number of visits as their routine data indicated. Most 
(76.2%) patients reported more (by 3.8 visits on average, 
figure 2A). There was greater agreement between routine 
and self- report data at T3; 11 (32.4%) patients reported 
the same number of visits as their routine data (figure 2B).
Blinding
The researcher correctly guessed which of the two 
treatment arms 35 patient participants had been allo-
cated to by the randomisation process; unblinding rate 
68.6% (CI 54.1% to 80.9%). The chance- corrected 
kappa statistic of 0.37 (CI 0.12 to 0.63) equated to ‘fair’ 
agreement.
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Table 7 Required sample size for a deinitive trial to detect 
estimated effect of SAFE+TAU on ED use
Dispersion 
parameter (k)
~47% Reduction (from 3.4 to 1.8 visits) in 
12 months compared with TAU
N per group
(Į=0.05; 80% 
power, ȕ=0.2)
N per group
(Į=0.05; 90% power, 
ȕ=0.1)
0.17 123 164
0.5 191 255
0.69 230 308
1 293 393
1.21 337 451
Dispersion parameter taken from the adjusted NBR model in the 
pilot RCT (ie, k=0.69; 95% CI: 0.17 to 1.21); see table 6.
ED, emergency department; RCT, randomised controlled trial; 
SAFE, Seizure First Aid Training For Epilepsy; TAU, treatment- 
as- usual.
Safety
No serious adverse events related to participation 
occurred (online supplementary file 7).
Participant feedback
Thirty- two (68.1%) patients and 20 (62.5%) SOs 
completed the T3 feedback questionnaire. All but one 
said they would participate in such a trial again; partici-
pants indicated they perceived benefits from SAFE.
Sample size calculation
Based on the estimated effect of SAFE (see At 12 months, 
effect of SAFE section), table 7 shows the number of 
patient participants required per group for a definitive 
trial. If the central value in the estimate range for the 
dispersion parameter k of 0.69 is used and 90% power 
stipulated, then a total starting sample of 674 patient 
participants (ie, (308×2)+58) would need to be recruited. 
This accounts for the 9.4% of recruited patients who (on 
the basis of the pilot trial) would be anticipated to with-
draw consent to access their routine ED data. In the pilot 
trial, 5 of the 53 patients recruited withdrew consent.
Microcosting
Delivering SAFE was estimated to cost £333 (CR £288 to 
£380) per patient (with or without a SO). When including 
the cost SAFE’s development (£181 per person), the 
mean cost per attendee, based on all 55 participants in 
SAFE+TAU or TAU groups who ultimately attended a 
SAFE session, was £375 (CR £348 to £402, online supple-
mentary file 8). This reduced to £194 (CR £167 to 
£221) when excluding sunk costs. Staff time accounted 
for 50.01% of the cost of SAFE’s delivery. SAFE’s facili-
tator was not local to the trial area. Thus, an analysis of 
facilitator costs without travel expenses (time and cost), 
reduced the mean cost by 21.08% from £194 (CR £167 
to £221) to £152 (CR £124 to £179) per delegate (£261 
per patient with or without SO). The annual fixed cost 
of setting up and running SAFE was £1122 (+£35.07 per 
patient, based on 32 patients/year attending with or 
without SO).
DISCuSSIOn
The pilot trial was successful, providing estimates of 
key parameters, including recruitment and retention. 
An informed decision regarding feasibility and optimal 
design of a definitive trial of SAFE can now be made.
Positives from pilot for feasibility and design of deinitive trial
Identiication, treatment and safety
The pilot trial indicates it is possible to identify, consent, 
randomise and safely treat persons from the target popu-
lation within a definitive trial. This was not a given since 
no RCT had focused recruitment on them.
Retention and measuring ED use
By using routine data as the basis of the primary outcome 
measure, a definitive trial should not be affected by attri-
tion. It permitted 12- month data to be secured for 94% 
of pilot participants. Despite having shorter follow- ups 
(6 months), 151 definitive RCTs funded by the National 
Institute for Health Research () secured outcome data for 
89% of patients.51 The use of routine data in our pilot 
trial meant it satisfied the retention progression criterion. 
It would not have been met if self- report data were relied 
on (only 67% of patients provided it). This leads us to 
recommend ED use be measured using routine data.
Another reason for the recommendation is its cost 
would be low compared with employing staff to obtain 
self- report data. Routine data would also prevent a defin-
itive trial from exposure to apparent recall bias, with 
patients seemingly over reporting ED use (it has been 
asserted that bias is not an issue for ‘‘big ticket’’ service 
items).52 53
However, our pilot trial does caution that provision 
of routine data is slow and not straightforward. It took 
8.5 months to obtain. In principle, such applications 
should be processed within 2 months.54 Data providers 
should attend to such issues as those funding and 
designing trials need confidence that data can be secured 
and realistic estimates. It is also worth noting that some 
of the ED visits attributed to our participants may not 
have been epilepsy related. Since a diagnostic code is not 
recorded for ~35% of ED visits, we asked NHS Digital to 
inform us of any ED visits recorded for our participants.25
negatives from pilot trial for feasibility and design of 
deinitive trial
Consent
Only a small proportion (10.6%) of identified patients 
were eligible and willing (12.5%) to take part, meaning 
the progression criterion that ≥20% of eligible patients 
agree to participate was not met.
The progression criterion was stated a priori because 
when uptake is so low there is the real possibility that 
those who are and are not taking part differ. We compared 
the age and deprivation of patients who did and did not 
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take part and found no obvious differences. We do not 
know whether they differed on other indices since access 
to non- participants’ medical records was not ethically 
permissible. One indication the pilot trial might not have 
recruited a representative sample was the high proportion 
of patients seeing a neurologist in the prior 12 months 
(~75%). Evidence suggests this should be closer to 38%.1
The consent rate also raises questions over the like-
lihood of a definitive trial being funded since it would 
make it expensive. On average, each pilot site generated 
17.6 patient accruals from 18 months of attendances. To 
achieve a sample size of ~674 PWE, a definitive trial could 
thus require ~39 sites (half of England’s EDs). This is 
2.5 times more sites than in recent NIHR funded RCTs52 
which already had a mean cost of ~£1.3 million.55 A defin-
itive RCT of SAFE might thus not represent acceptable 
value for money to funders.56
Epilepsy and its consequences (eg, seizures, memory 
difficulties, no driving license) make recruiting PWE 
challenging. The consent rate in the pilot is neverthe-
less low. In the largest RCT of self- management (Self- 
Management education for adults with poorlycontrolled 
epILEpsy [SMILE] trial), 37% of the people with uncon-
trolled epilepsy invited took part.57 The characteristics 
of the patients from ED agreeing to participate in our 
pilot suggest that one reason for the low uptake might 
be stigma; 82% felt some (21.6% felt highly stigmatised). 
This is higher than in the wider epilepsy population; 
63% of SMILE’s sample felt stigmatised (12.5% highly).58 
Stigma can make PWE feel ashamed and reluctant to talk 
about epilepsy. This could explain why the target popu-
lation is so challenging to recruit. Unfortunately, it is 
unclear how to revise recruitment to mitigate against this.
Evidence- based strategies were employed in the pilot to 
maximise recruitment,30 and invitation materials copro-
duced with patients. It is generally considered preferable 
for a usual care provider, with whom a patient has an 
established relationship, to invite a person into research. 
Difficulties identifying the target population (see Back-
ground section) meant we had local ED clinicians do the 
inviting. A future trial might consider asking EDs to iden-
tify ostensibly eligible patients, but for the general practi-
tioners of the identified patients to do the inviting. This 
may boost recruitment.59
Effect of intervention
Our pilot trial estimated SAFE’s effect to be modest 
(reducing ED visits from 2.1 over 12 months to 1.8). This 
has negative consequences for a definitive trial, not least 
because it requires it to have a large sample to detect the 
effect. Efficacy was not our pilot trial’s primary focus and 
the estimate may be imprecise. Indeed, it might be that 
those who declined to participate in the trial and who 
appeared to differ in some important ways, might have 
benefited more. Previous evidence does suggest it is in 
the region expected.
Specifically, only one RCT—by Sajatovic et al60—
has considered change in ED use following epilepsy 
self- management.61 Conducted in the USA, it compared 
‘Self- MAnagement for people with epilepsy and ahistoRy 
of negative health evenTs' (SMART)—an 8- session group 
intervention—to wait list control. No significant change 
between groups was found in subsequent ED/hospitalisa-
tion use. For SMART, it reduced from a mean of 1.22 by 
0 .44 over the 6 months following randomisation. For the 
controls it reduced from 2.4 by −1.26 visits.
Judgement regarding progression to deinitive trial
Thabane et al62 provide a framework for judging whether 
to progress to a definitive trial. In satisfying only one 
progression criteria, a definitive trial based on the pilot 
trial’s design is not feasible. We have also not identified 
any modifications that will make it feasible. We therefore 
recommend not proceeding.
Strengths and limitationss
Strengths include the pilot trial being reported according 
to guidelines,63 allocations being concealed, that patients 
were recruited from sites similar to those likely for a 
definitive trial and we included a microcosting of SAFE’s 
delivery.
The pilot trial is not without potential weaknesses. 
Most importantly, despite recruited patient participants 
stating sufficient ED use when screened, routine data 
subsequently suggested ~40% did not meet the inclusion 
criteria. This could limit our findings’ external validity 
and attenuate SAFE’s effect. Another potential limitation 
is we estimated the effect of SAFE only on the proposed 
primary measure. We did not estimate its wider effects, 
including on duration of ED visits and admissions.
COnCluSIOn
A definitive trial of SAFE is not currently feasible. 
Research is required to determine how people from the 
target population can be better recruited.
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